Bang Ngoc Dao

Bang Ngoc Dao


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
TNTuan Chi Nguyen
Tuan Chi Nguyen
DNDung Tien Nguyen
Dung Tien Nguyen
BDBang Ngoc Dao
Bang Ngoc Dao
VNVan Dung Nguyen
Van Dung Nguyen
NPNhung Thi Kim Pham
Nhung Thi Kim Pham
TTThang Tien Ta
Thang Tien Ta
(1) Background: Isoniazid resistance in Mycobacterium tuberculosis is primarily mediated by mutations in katG and inhA genes, yet the molecular characteristics of coding region mutations and their clinical correlations in Vietnamese patients remain incompletely understood; (2) Methods: We conducted a cross-sectional study analyzing exon mutations in katG and inhA genes using Sanger sequencing in 56 isoniazid-resistant pulmonary tuberculosis patients treated at the National Lung Hospital from January 2023 to June 2024, with comprehensive clinical and paraclinical data collection; (3) Results: Exon mutations in katG were detected in 11 patients (19.6%) and inhA in 7 patients (12.5%), with no concurrent mutations. The Ser315Thr mutation was present in all katG-positive cases (100%), while all inhA mutations were concentrated in codon cluster 233-240 with 63/96 being amino acid-changing variants. Patients with katG or inhA mutations had significantly higher rates of pulmonary rales compared to those without mutations (90.9% and 85.7% vs. 34.2%, p < 0.001), and inhA mutations were exclusively found in multidrug-resistant tuberculosis cases (p = 0.012); (4) Conclusions: Our findings identify codon cluster 233-240 as a novel inhA mutation hotspot in Vietnamese strains and demonstrate significant associations between specific mutations and disease severity. The exclusive presence of inhA mutations in MDR-TB cases and the correlation between genotype and clinical manifestations support the implementation of genotype-guided diagnostic and therapeutic strategies for isoniazid-resistant tuberculosis.